



=====

EXTRAORDINARY GENERAL MEETING

=====

The year two thousand twenty-five.

On twenty-two May.

In Ghent, Kortrijksesteenweg 1112 (box 102), at the registered office of the Company.

Before Us, **Stijn RAES**, notary at Ghent, second canton.

IS HELD:

the extraordinary general meeting of the holders of securities issued by "**Sequana Medical**", limited liability company (*naamloze vennootschap*) under Belgian law, in its capacity as listed company, with registered office at Sint-Denijs-Westrem (B-9051 Gent), Kortrijksesteenweg 1112 (box 102), with company number VAT BE0707.821.866 RLP Ghent, section Ghent, Belgium (the "**Company**").

[...]

4. Verification of the attendance quorum

At present, there are a total of fifty-four million, six hundred seventy-one thousand, seventy-four (54,671,074) shares representing the share capital of the Company, without nominal value, on the registration date (being Thursday, 8 May 2025 at midnight (12.00 am, Belgian time)).

The Chairperson stated that in accordance with Article 38 of the Articles of Association *juncto* Article 7:153 of the Belgian Companies and Associations Code, the meeting can only validly deliberate and resolve on the agenda items 2., 4. and 6 if the shareholders present or represented represent at least half of the share capital, since the agenda includes an amendment to the Articles of Association. There is no attendance quorum for deliberating and resolving upon the other items of the agenda of the extraordinary general meeting of shareholders.

The bureau noted that, according to the attendance lists, the shareholders represented at the meeting held thirty million, six hundred sixty-two thousand, fifty-five (30,662,055) shares out of a total of fifty-four million, six hundred seventy-one thousand, seventy-four (54,671,074) shares issued by the Company, or (rounded) fifty-six point zero eight percent (56.08%) of the total number of shares representing the Company's share capital.

Consequently, the bureau determined that the meeting could validly deliberate and decide on the items of the agenda.

[...]

DELIBERATION - DECISIONS

The Chairperson then presented each of the proposed resolutions on the agenda to the shareholders to vote.

The Chairperson noted that the exact totals of the votes by mail and the votes at the meeting will be recorded in the minutes.

[...]

FIRST RESOLUTION: Submission of the special report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the authorised capital

Acknowledgement and discussion of the special report of the Board of Directors in accordance with Article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the powers granted to the Board of Directors under the authorised capital, as set out below in the second resolution of the extraordinary general shareholders' meeting, and setting out the specific circumstances in which the Board of Directors will be able to use its powers under the authorised capital, as well as the purposes that it should pursue hereby.

ACKNOWLEDGEMENT

The meeting discharged the Chairman from reading the special report of the Board of Directors in accordance with article 7:199 of the Belgian Companies and Associations Code on the proposal to renew the authorised capital.

KEEPING

The executed report of the management body is kept in the archives of the Company.

SECOND RESOLUTION: Renewal of the authorisation to the Board of Directors to increase the share capital within the framework of the authorised capital

The extraordinary general shareholders' meeting resolves to renew the authorisation to the Board of Directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorisation, with an aggregate amount equal to up to 100% of the current amount of the share capital of the Company (namely, five million, six hundred sixty-four thousand, two hundred sixty-nine euros, ninety-six cents (5,664,269.96 EUR)), and this in accordance with the terms and conditions set forth in the special report of the Board of Directors prepared in accordance with Article 7:199 of the Belgian Companies and Associations Code, as referred to in the first resolution of this extraordinary general shareholders' meeting. Consequently, the extraordinary general shareholders' meeting resolves to delete the first and third paragraph of Article 8 "Authorised capital" of the articles of association of the Company entirely and to replace the first and third paragraph of Article 8 respectively with the following text:

- (a) text of the first paragraph: "*The board of directors is authorised to increase the share capital of the company on one or several occasions by a maximum aggregate amount of five million, six*

hundred sixty-four thousand, two hundred sixty-nine euros, ninety-six cents (5,664,269.96 EUR)."

- (b) text of the third paragraph: *"This authorisation is valid for a period of five years as from the date of publication in the Annexes to the Belgian Official Gazette of an extract of the minutes of the extraordinary general shareholders' meeting of the company held on 22 May 2025."*

VOTING

The proposal was put to the vote.

The proposal is passed as set out below:

1. Number of shares for which votes have been validly cast:
30,662,055
2. Percentage that the abovementioned number of shares represent in the share capital:
56.08%
3. Number of votes validly cast:
30,662,055

of which,

FOR: 28,462,724

AGAINST: 2,199,331

ABSTENTION: 0

The proposal has therefore been adopted.

THIRD RESOLUTION: Submission of reports in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code relating to the proposal to issue 1,000,000 new 2025 Share Options

The meeting discharged the Chairman from reading the following reports relating to the proposal to issue the 1,000,000 new 2025 Share Options (as defined below), which are being submitted today:

- (a) the report of the Board of Directors of the Company in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 1,000,000 new subscription rights for shares of the Company (the "2025 Share Options"), pursuant to a share option plan named the "2025 Share Option Plan", and to dis-apply, in the interest of the Company, the statutory preferential subscription right of the existing shareholders of the Company and, insofar as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of Article 1:27 of the Belgian Companies and Associations Code (the "Selected Participants"); and

- (b) the report of the Statutory Auditor of the Company in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 1,000,000 2025 Share Options, and to dis-apply, in the interest of the Company, the statutory preferential subscription right of the existing shareholders of the Company and, insofar as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants.

DEPOSIT

The aforementioned reports are attached hereto and will be registered together and will be deposited at the competent clerk's office of the enterprise court.

FOURTH RESOLUTION: Proposal to issue the 1,000,000 new 2025 Share Options to the benefit of the Selected Participants

The extraordinary general shareholders' meeting resolves to approve the issuance of 1,000,000 2025 Share Options, pursuant to a share option plan named the "2025 Share Option Plan", and to dis-apply, in the interest of the Company, the statutory preferential subscription right of the existing shareholders of the Company and, insofar as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants. In view thereof, the general shareholders' meeting resolves as follows:

- (a) Terms and conditions of the 2025 Share Options: The terms and conditions of the 2025 Share Options (including, but not limited to, the exercise price of the 2025 Share Options) shall be as set out in the annex to the report of the Board of Directors referred to in item (a) of the third resolution (for the purpose of this resolution, the "Plan"), a copy of which shall remain attached to the minutes reflecting the present resolution. The 2025 Share Options have a term of ten years as from the date on which they are issued.
- (b) Underlying shares: Each 2025 Share Option shall entitle the holder thereof to subscribe for one (1) new share to be issued by the Company. The new shares to be issued at the occasion of the exercise of the 2025 Share Options shall be issued as fully paid-up, have the same rights and benefits, and have the same (pari passu) rank in all respects, including the entitlement to dividends and other distributions, as the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and other distributions in respect of which the relevant record date or expiry date falls on or after the date of issue of the shares.
- (c) Disapplication of the statutory preferential subscription right to the benefit of the Selected Participants: The general shareholders' meeting resolves, in accordance with Article 7:191

of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the statutory preferential subscription right of the existing shareholders of the Company and, insofar as needed, of the existing holders of outstanding subscription rights (share options) of the Company, to the benefit of the Selected Participants (it being the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of Article 1:27 of the Belgian Companies and Associations Code), and to approve the possibility for the Company to grant the 2025 Share Options to the Selected Participants, as further explained in the report of the Board of Directors referred to in item (a) of the third resolution and the terms and conditions of the Plan.

- (d) Confirmation of the subscription of the 2025 Share Options by the Company: The general shareholders' meeting resolves to approve and confirm that the Company will be able to subscribe to the 2025 Share Options, in order to create a pool of outstanding 2025 Share Options available for further grants to Selected Participants. The Company may not, however, exercise the 2025 Share Options for its own account.
- (e) Conditional capital increase and issue of new shares: The general shareholders' meeting resolves, subject to, and to the extent of the exercise of 2025 Share Options, to increase the Company's share capital and to issue the relevant number of new shares issuable upon the exercise of the 2025 Share Options. Subject to, and in accordance with, the provisions of the Plan, upon exercise of the 2025 Share Options and issue of new shares, the aggregate amount of the exercise price of the 2025 Share Options will be allocated to the share capital of the Company. If the applicable exercise price per 2025 Share Option, per issued underlying new share, exceeds the fractional value of the existing shares immediately prior to the capital increase, then the applicable total issue price will be allocated as such that per issued new share (i) a part of the applicable aggregate exercise price equal to the fractional value of the existing shares immediately prior to the capital increase will be booked as share capital, and (ii) the balance of the applicable aggregate exercise price will be booked as issue premium. Following the capital increase and the issuance of new shares, each share (existing and new) shall represent the same fraction of the share capital of the Company.
- (f) Issue premium: Each issue premium that will be booked in connection with the 2025 Share Options, shall be booked on the liabilities side of the Company's balance sheet as net equity. The account on which the issue premium is booked shall, like the share capital, serve as a guarantee for third parties and can,

notwithstanding the possibility of capitalisation of such reserves, only be reduced on the basis of a lawful resolution of the general shareholders' meeting of the Company passed in the manner required for an amendment to the Company's articles of association.

- (g) Powers of attorney: The Board of Directors is authorised to implement and execute the resolutions passed by the general shareholders' meeting in connection with the 2025 Share Options, and to take all steps and carry out all formalities that shall be required by virtue of the Plan, the Company's articles of association and applicable law in order to issue or transfer the shares upon exercise of the 2025 Share Options. Furthermore, each Director of the Company, and each member of the executive management of the Company, each such person acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power, upon exercise of the 2025 Share Options, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise, (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company's articles of association in order to reflect the new share capital and number of outstanding shares following the exercise of the 2025 Share Options, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise of the 2025 Share Options to trading on the regulated market of Euronext Brussels (or such other markets on which the Company's shares will be trading at that time).
- (h) Waiver: The general shareholders' meeting acknowledges that the 2025 Share Options to be granted under the "2025 Share Option Plan" shall not be considered as a "variable remuneration", "fixed remuneration" or "annual remuneration" within the meaning of the Belgian Companies and Associations Code (including for, but not limited to, the purposes of Articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 and 7:121 of the Belgian Companies and Associations Code) and the 2020 Belgian Corporate Governance Code (including for, but not limited to, the purposes of provision 7.11 of the 2020 Belgian Corporate Governance Code). In accordance with Article 7:91, 7:108 and 7:121 (as applicable) of the Belgian Companies and Associations Code, the general

- shareholders' meetings approves the vesting conditions and mechanisms of the 2025 Share Options, as included in the Plan.
- (i) Approval in accordance with Article 7:151 of the Belgian Companies and Associations Code: The general shareholders' meeting takes note, approves and ratifies, insofar as needed and applicable, in accordance with Article 7:151 of the Belgian Companies and Associations Code, all clauses included in the Plan, which fall or could be considered to fall under the scope of Article 7:151 of the Belgian Companies and Associations Code (relating to the grant of rights to third parties that substantially affect the Company's assets and liabilities, or create a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change of control exercised over it), including, without limitation, the automatic accelerated vesting mechanism upon acquisition as defined in the Plan. The general shareholders' meeting also grants a special power of attorney to each Director of the Company, to the notary public Stijn Raes, and to Fin-2K BV, represented by Kirsten Van Bockstaele (Chief Financial Officer) (each a "Proxy Holder", for the purposes of this resolution 4), each Proxy Holder acting singly and with the right of substitution, to complete the formalities required by Article 7:151 of the Belgian Companies and Associations Code with respect to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the Annexes to the Belgian Official Gazette.

VOTING

The proposal was put to the vote.

The proposal is passed as set out below:

1. Number of shares for which votes have been validly cast:
30,662,055
2. Percentage that the abovementioned number of shares represent in the share capital:
56.08%
3. Number of votes validly cast:
30,662,055

of which,

FOR: 28,462,724

AGAINST: 2,199,331

ABSTENTION: 0

The proposal has therefore been adopted.

FIFTH RESOLUTION: Submission of reports in accordance with Articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code relating to the proposal to issue 2,620,000 GEM Warrants

On 18 March 2025, the Company announced that it had entered into a share subscription facility agreement (the "SSFA") with, among others GEM Global Yield LLC SCS (the "Investor"), pursuant to which the Investor has agreed, subject to certain conditions, amongst other things, to commit, for a maximum term of three years, an initial aggregate amount of up to EUR 20 million (including issue premium), with the option for the Company to further increase the aggregate amount to up to EUR 60 million (including issue premium) (once the aforementioned EUR 20 million has been drawn down). As consideration for entering into the SSFA by the Investor, the Company and the Investor have agreed to submit the issuance of 2,620,000 GEM Warrants (as defined below) for approval to the extraordinary general shareholders' meeting of the Company. In this context, the following reports in respect of the proposed issuance of the 2,620,000 GEM Warrants are submitted to the general shareholders' meeting.

The meeting discharged the Chairman from reading the following reports relating to the proposal to issue the 2,620,000 GEM Warrants, which are being submitted today:

- (a) the report of the Board of Directors of the Company in accordance with Articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code in relation to the proposal (i) to issue 2,620,000 subscription rights for new shares of the Company to the benefit of the Investor (and its permitted successors and assigns), named the "GEM Warrants" (hereinafter the "GEM Warrants"), and (ii) to dis-apply, in the interest of the Company, and for the purpose of the issuance of the GEM Warrants to the benefit of the Investor as agreed in the SSFA, the statutory preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Investor (and its permitted successors and assigns); and
- (b) the report of the Statutory Auditor of the Company in accordance with Articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code in relation to the proposal (i) to issue 2,620,000 GEM Warrants, and (ii) to dis-apply, in the interest of the Company and for the purpose of the issuance of the 2,620,000 GEM Warrants, the statutory preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Investor (and its permitted successors and assigns).

DEPOSIT

The aforementioned reports are attached hereto and will be registered together and will be deposited at the competent clerk's office of the enterprise court.

SIXTH RESOLUTION: Proposal to issue the 2,620,000 GEM Warrants to the benefit of the Investor

The extraordinary general shareholders' meeting resolves to approve (i) the issuance of the 2,620,000 GEM Warrants (as defined above) to the benefit of the Investor (and its permitted successors and assigns) (giving the holder the right to subscribe to 2,620,000 new shares of the Company), exercisable at an exercise price per underlying new share equal to the lower of (i) EUR 1.95, and (ii) 117% of the average of the volume weighted average price of the shares of the Company during the ten (10) trading days preceding the date on which the GEM Warrants will be issued by the extraordinary general shareholders' meeting of the Company, and (ii) the dis-application, in the interest of the Company and for the purpose of the issuance of the GEM Warrants to the benefit of the Investor as agreed in the SSFA, of the statutory preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, to the benefit of the Investor (and its permitted successors and assigns). In view thereof, the extraordinary general shareholders' meeting resolves as follows:

- (a) Terms and conditions of the GEM Warrants: The terms and conditions of the GEM Warrants shall be as set out in the annex to the report of the Board of Directors referred to in item (a) of the fifth resolution (for the purpose of this resolution, the "Conditions"), a copy of which shall remain attached to the minutes reflecting the present resolution. The main terms of the GEM Warrants can, for informational purposes, be summarised as follows:
 - (i) Issuer: The Company (Sequana Medical NV).
 - (ii) Subscription rights for ordinary shares: Each GEM Warrant gives the holder the right to subscribe to one (1) new ordinary share that will be issued by the Company (subject to the conditions and limitations set out in the Conditions), provided that the GEM Warrants can only be exercised in respect of a whole number of GEM Warrants and not in respect of a fraction of a GEM Warrant. No fractions of shares will be issued upon exercise of the GEM Warrants. The number of ordinary shares that will be issued upon the exercise of the GEM Warrants is subject to certain adjustments, as set out in the Conditions.
 - (iii) Exercise price: The GEM Warrants can be exercised at an exercise price per underlying new share (the "Exercise Price") equal to the lower of (i) EUR 1.95, and (ii) 117% of

the average of the volume weighted average price of the shares of the Company during the ten (10) trading days preceding the date on which the GEM Warrants will be issued by the extraordinary general shareholders' meeting of the Company. The aforementioned Exercise Price is subject to certain adjustments in case of, among others, any consolidation, reclassification or subdivision of the shares of the Company, as well as certain other share issuances and transactions, as set out in the Conditions.

- (iv) Duration: The GEM Warrants have a term that starts on the date on which the GEM Warrants are issued by the extraordinary shareholders' meeting (the "Issue Date") and expires on the date falling three years after the Issue Date, or if that day is not a business day, on the next business day (the "Expiry Date").
- (v) Exercisability: Subject to the conditions and limitations as set out in the Conditions, the GEM Warrants can be exercised by the holder at any moment and from time to time on any business day from the opening of trading on the Issue Date and until no later than 5 p.m. (Brussels time) on the Expiry Date. Any GEM Warrant not exercised by that time shall become void by operation of law and the rights of the holder to exercise such GEM Warrant shall lapse.
- (vi) Nature of the shares to be issued upon exercise: Each GEM Warrant shall entitle the holder thereof to subscribe to one (1) new ordinary share that will be issued by the Company. The new ordinary shares shall be issued as fully paid-up, have the same rights and benefits, and have the same (pari passu) rank in all respects, including the entitlement to dividends and other distributions, as the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and other distributions in respect of which the relevant record date or expiry date falls on or after the date of issue of the shares.
- (vii) Listing of the underlying shares: The new shares to be issued upon exercise of the GEM Warrants will have to be admitted to listing and trading on the regulated market of Euronext Brussels.
- (viii) Form of the GEM Warrants: The GEM Warrants are issued, and must remain, in registered form.
- (ix) No listing of the GEM Warrants: The GEM Warrants will not be listed on any stock exchange, regulated market or similar securities market at any time.

- (x) Transferability of the GEM Warrants: The holder has the right to freely transfer or assign the GEM Warrants without the prior consent of the Company, in accordance with the limitations included in the Conditions.
- (b) Capital increase and allocation of the Exercise Price: Upon each exercise of the GEM Warrants and the resulting issuance of new shares, the Company's share capital will be increased. Subject to, and in accordance with, the provisions of the Conditions, upon exercise of the GEM Warrants and issue of new shares, the aggregate amount of the applicable Exercise Price of the relevant GEM Warrants will be allocated to the share capital of the Company. If the applicable Exercise Price, per underlying new share issued, is greater than the fractional value of the existing shares immediately prior to the capital increase, then the applicable aggregate issue price shall be allocated in such a manner that per new share issued (i) a part of the applicable aggregate Exercise Price equal to the fractional value of the existing shares immediately prior to the capital increase shall be booked as share capital, and (ii) the balance of the applicable aggregate Exercise Price shall be booked as issue premium. This issue premium shall be booked on the liabilities side of the Company's balance sheet as net equity. The account on which the issue premium is booked shall, like the share capital, serve as a guarantee for third parties and can, notwithstanding the possibility of capitalisation of such reserves, only be reduced on the basis of a lawful resolution of the general shareholders' meeting of the Company passed in the manner required for an amendment to the Company's articles of association. Following the capital increase and the issuance of new shares, each of the shares (existing and new) shall represent the same fraction of the Company's share capital.
- (c) Disapplication of the statutory preferential subscription right to the benefit of the Investor (and its permitted successors and assigns): The statutory preferential subscription right of the existing shareholders of the Company and, as far as needed, of the holders of outstanding subscription rights (share options) of the Company, will be dis-applied, in the interest of the Company, in accordance with Articles 7:191 and 7:193 of the Belgian Companies and Associations Code, to the benefit of the Investor (and its permitted successors and assigns), for the purpose of the issuance of the GEM Warrants to the benefit of the Investor, as further explained in the report of the Board of Directors mentioned in item (a) of the fifth resolution. The Investor is a company organised and existing under the laws of Luxembourg with registered office at 12C, rue Guillaume J. Kroll, L-1882,

Luxembourg. The Investor is not a member of the personnel within the meaning of Article 1:27 of the Belgian Companies and Associations Code.

- (d) Powers of attorney: The Board of Directors is authorised to implement and execute the resolutions passed by the general shareholders' meeting in connection with the issuance of the GEM Warrants, and to take all steps and complete all formalities that shall be required by virtue of the Conditions of the GEM Warrants, the Company's articles of association and applicable law in order to issue or transfer the shares upon exercise of the GEM Warrants. Furthermore, each director of the Company and Fin-2K BV, represented by Kirsten Van Bockstaele (Chief Financial Officer), each such person acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power, upon exercise of the GEM Warrants, (i) to proceed with the recording of (A) the capital increase and the issuance of new shares resulting from such exercise, (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company's articles of association in order to reflect the new share capital and number of outstanding shares following the exercise of the GEM Warrants, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise of the GEM Warrants to trading on the regulated market of Euronext Brussels (or such other markets on which the Company's shares will be trading at that time).
- (e) Approval in accordance with Article 7:151 of the Belgian Companies and Associations Code: The general shareholders' meeting takes note, approves and ratifies, insofar as needed and applicable, in accordance with Article 7:151 of the Belgian Companies and Associations Code, all clauses included in the Conditions, which fall or could be considered to fall under the scope of Article 7:151 of the Belgian Companies and Associations Code (relating to the grant of rights to third parties that substantially affect the Company's assets and liabilities, or create a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change of control exercised over it), including, without limitation, Condition 7 regarding organic changes. The general shareholders' meeting also grants

a special power of attorney to each Director of the Company, to the notary public Stijn Raes and to Fin-2K BV, represented by Kirsten Van Bockstaele (Chief Financial Officer) (each a "Proxy Holder", for the purposes of this resolution 6), each Proxy Holder acting singly and with the right of substitution, to complete the formalities required by Article 7:151 of the Belgian Companies and Associations Code with respect to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the Annexes to the Belgian Official Gazette.

VOTING

The proposal was put to the vote.

The proposal is passed as set out below:

1. Number of shares for which votes have been validly cast:
30,662,055
2. Percentage that the abovementioned number of shares represent in the share capital:
56.08%
3. Number of votes validly cast:
30,662,055

of which,

FOR: 28,462,724

AGAINST: 2,199,331

ABSTENTION: 0

The proposal has therefore been adopted.

[...]

CLOSING OF THE MEETING

There being no further business, the meeting is adjourned at 09:26 am.

[...]